GlassScriptPhysician profile
Beverly Gilraine
NPI 1326000605
$5,103.72
in general payments reported to CMS, 2019-2025
13 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,213 · 2022: $1,274 · 2023: $1,676 · 2024: $803 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.82 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,355.18 | 2021-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $733.61 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $726.45 | 2021-2024 | |
| Lundbeck LLC | $725.99 | 2021-2024 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $696.81 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.12 | 2022-2024 | Caplyta |
| Alkermes, INC. | $247.24 | 2021-2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $188.63 | 2021-2023 | Trintellix |
| Eisai INC. | $48.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $37.71 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $36.80 | 2021 | |
| Corium, LLC | $22.17 | 2022 | |
| Allergan, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Gilraine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.